Next Article in Journal
Antibacterial Activity of Alkaloid Fractions from Berberis microphylla G. Forst and Study of Synergism with Ampicillin and Cephalothin
Previous Article in Journal
The Protective Effects of Alisol A 24-Acetate from Alisma canaliculatum on Ovariectomy Induced Bone Loss in Vivo
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina

by
Cristiane Bezerra da Silva
1,*,
Arnildo Pott
2,
Selene Elifio-Esposito
3,
Luciane Dalarmi
1,
Kátia Fialho do Nascimento
4,
Ligia Moura Burci
1,
Maislian De Oliveira
1,
Josiane De Fátima Gaspari Dias
1,
Sandra Maria Warumby Zanin
1,
Obdulio Gomes Miguel
1 and
Marilis Dallarmi Miguel
1
1
Department of Pharmacy, Federal University of Paraná (UFPR), Av. Pref. Lothário Meissner 3400, Jardim Botânico, Curitiba 80210-170, Brazil
2
Department of Biology, Federal University of Mato Grosso do Sul (UFMS), Av. Senador Filinto Müller, Campo Grande 79046-460, Brazil
3
Post-Graduation in Health Sciences, Pontíficia Universidade Católica do Paraná, Imaculada Conceição, 1155, Prado Velho, Curitiba 80215-901, Brazil
4
Department of Celular Biology, Federal University of Paraná (UFPR), Centro Politécnico, Jardim das Américas, Curitiba 81530-900, Brazil
*
Author to whom correspondence should be addressed.
Molecules 2016, 21(1), 53; https://doi.org/10.3390/molecules21010053
Submission received: 25 May 2015 / Revised: 26 July 2015 / Accepted: 15 September 2015 / Published: 11 January 2016
(This article belongs to the Section Medicinal Chemistry)

Abstract

:
Dugesia tigrina is a non-parasitic platyhelminth, which has been recently utilized in pharmacological models, regarding the nervous system, as it presents a wide sensitivity to drugs. Our trials aimed to propose a model for an in vivo screening of substances with inhibitory activity of the enzyme acetylcholinesterase. Trials were performed with four drugs commercialized in Brazil: donepezil, tacrine, galantamine and rivastigmine, utilized in the control of Alzheimer’s disease, to inhibit the activity of acetylcholinesterase. We tested five concentrations of the drugs, with an exposure of 24 h, and the mortality and the inhibition of acetylcholinesterase planarian seizure-like activity (pSLA) and planarian locomotor velocity (pLMV) were measured. Galantamine showed high anticholinesterasic activity when compared to the other drugs, with a reduction of 0.05 μmol·min−1 and 63% of convulsant activity, presenting screw-like movement and hypokinesia, with pLMV of 65 crossed lines during 5 min. Our results showed for the first time the anticholinesterasic and convulsant effect, in addition to the decrease in locomotion induced by those drugs in a model of invertebrates. The experimental model proposed is simple and low cost and could be utilized in the screening of substances with anticholinesterasic action.

1. Introduction

Alzheimer’s disease is known as a degenerative and progressive disorder of the brain and is considered the most common form of dementia of the elderly, especially in developed countries. The disease is associated with a loss of the cholinergic system with a reduction of the levels of acetylcholine in areas of the brain that deal with learning, memory, behavior and emotional responses [1]. Thus, the most promising approach for symptomatic treatment of Alzheimer’s disease is to increase the synaptic levels of acetylcholine in the brain through inhibition of acetylcholinesterase (AChE). The inhibitors of AChE, such as galantamine, donepezil, rivastigmine and tacrine, are the main medicines for clinical management of the disease and are widely applied in Brazil [2].
Different pharmacological models, mainly those using rodents, were proposed to select substances that could act as AChE inhibitors [3,4,5,6,7]. However, the cost of the acquisition and maintenance of animals in vivo, the need for an adequate physical structure, care in handling and minimizing suffering justifies the demand of alternative methods of low cost that are more accessible and that have a higher number of individuals, as well as to achieve results in less time than conventional trials.
Species of planarians have been shown to be extremely precise and relevant models in pharmacological studies, once they exhibit cephalization, including the brain, which has many characteristics in common with the nervous system of more specialized species [8]. Among such characteristics, the general morphology and physiology of the neurons, the presence of dendritic spines and the utilization of various neurotransmitters found in mammals, including humans, are also present in planarians [9].
The species Dugesia tigrina (Platyhelminthes, class Turbellaria) is a free-living flatworm and has a central nervous system with bilateral symmetry [10]. The presence of a characteristic and moderately simple central nervous system was recently proven on the basis of electroencephalography [11] and allows the easiness of the manipulation and comprehension of drug effects on this species, once its genes and neurotransmitters were found to be the same as those found in vertebrates [12,13]. Therefore, planarians are a promising model experimental organism for the investigation of biochemical and functional interactions among the receptor systems of neurotransmitters and can display the pharmacological action of several drugs [14,15,16,17].
Therefore, the objective of our work was to verify if the drugs galantamine, donepezil, Rivastigmine and tacrine inhibit the action of acetylcholinesterase in D. tigrina, aiming to establish an in vivo model for screening substances that could be applied in the control of Alzheimer’s disease.

2. Results and Discussion

Our results demonstrated that D. tigrina is sensitive to the tested drugs. Galantamine had more accentuated effects than the other drugs, with 100% mortality under a concentration of 25 μg·mL−1 and LC50 of 8.3 μg·mL. Considerable LC50 was also observed for rivastigmine (17.4 μg·mL−1) (Table 1).
Table 1. Mortality (%) and LC50 of D. tigrina submitted to 4 different drugs and 5 concentrations after 24 h of exposure.
Table 1. Mortality (%) and LC50 of D. tigrina submitted to 4 different drugs and 5 concentrations after 24 h of exposure.
Mortality
DrugsControl5 μg·mL−110 μg·mL−115 μg·mL−120 μg·mL−125 μg·mL−1LC50Confidence Interval
Donepezil01 ns3 ns4 *5 *8 *>2520–45
Tacrine02 ns2 ns3 ns6 *10 *≤21.217.5–31.7
Rivastigmine01 ns3 ns5 *7 *12 *≤17.415–21
Galantamine04 *6 *12 *15 *15 *≤8.35.5–12.5
* Means differ by Dunnett’s test (p = 0.05); ns: non-significant; n = 3–15 planarians per group.
All drugs inhibited the activity of AChE in D. tigrina, in a similar way to trials conducted in experimental models with vertebrates. The lowest concentration did not inhibit the production of AChE compared to other concentrations, but D. tigrina was less sensitive to donepezil (0.011 μmol·min−1 at concentration of 25 μg·mL−1) (Figure 1A). Tacrine and rivastigmine had similar inhibitory activity (0.007 and 0.008 μmol·min−1 at a concentration of 25 μg·mL−1) (Figure 1B,C), and galantamine provoked more intense inhibitory effects with the production of AchE equal to 0.005 μmol·min−1 at a concentration of 25 μg·mL−1 (Figure 1D). The activity of AChE is significantly reduced by a concentration above 10 μg·mL−1.
Figure 1. Effects of donepezil (A), tacrine (B); rivastigmine (C) and galantamine (D) on the inhibition of acetylcholinesterase in Dugesia tigrina, after 24 h of exposure. * Means differ by Dunnett’s test (p = 0.05). n = 3–15 planarians per group.
Figure 1. Effects of donepezil (A), tacrine (B); rivastigmine (C) and galantamine (D) on the inhibition of acetylcholinesterase in Dugesia tigrina, after 24 h of exposure. * Means differ by Dunnett’s test (p = 0.05). n = 3–15 planarians per group.
Molecules 21 00053 g001
The observed effects evidenced the cholinergic action of the drugs on D. tigrina, indicating that this species can be utilized for the screening of substances with anticholinesterasic activity. Our results are similar to those found by various authors in studies on the inhibition of AChE activity of the drugs donepezil, tacrine, galantamine and rivastigmine [18,19,20,21,22,23].
The presence of receptors of acetylcholine in Platyhelminthes had already been demonstrated in D. tigrina, indicating considerable levels of AChE in vivo [24]. Hence, our results showed that D. tigrina is emerging as a promising experimental model for the investigation of biochemical and functional interactions among receptor systems of different neurotransmitters and for the pharmacological action of several drugs.
These results are similar to those obtained in mice after administration of anticholinesterase drugs. When administered to rats, they promote changes of cholinesterase activities in the rat blood and tissues, LC50 being observed at a concentration of 40.0 mg·kg−1 for tacrine [25], 3.0 mg·kg−1 for galantamine [26], 25.0 mg·kg−1 for donepezil [26] and 75.0 mg·kg−1 for rivastigmine [27] after 24 h of administration. These drugs are considered potent acetylcholinesterase inhibitors, have been shown to be effective in biochemical dysfunction induced in rats and are considered pseudo irreversible inhibitors. Although the reversible effect was not the focus of this work, the aforementioned results demonstrate a rapid absorption of the drug by planarians, resulting from the nervous system, which leads to a complete absorption. The exhibition presented by the doses demonstrated inhibitory activity in vivo similar to tests conducted with rats.
Figure 2 shows the cumulative planarian seizure-like activity (pSLA) exhibited by D. tigrina after exposure to the drugs at different concentrations. A concentration-dependent increase in pSLA was observed in the worms exposed to the different drugs. At a concentration of 25 μg·mL−1, the convulsive effects were less pronounced, and D. tigrina presented minimal movement after a 5-min exposure under all tested drugs (Figure 2A–D). At the concentration of 25 μg·mL−1, the convulsive effects were less pronounced, and D. tigrina presented minimal movement after a 5-min exposure under all tested drugs. Locomotor activity was visibly reduced in planarians exposed to the higher concentrations of drugs, and a major effect in locomotor retardation was observed for galantamine and donepezil. As the concentration was increased, the planarians started to exhibit hypokinesia, resulting in a still position. Planarians exposed to 5.0 μg·mL−1 of galantamine and rivastigmine exhibited a higher number of pSLA (Figure 2C,D). Donepezil and tacrine had similar convulsive effects, with 48 and 36 pSLA, respectively (Figure 2C,D). PSLA was most affected by galantamine, with 63 convulsive movements under the lowest concentration (5 μg·mL) and four movements at the concentration of 25 μg·mL−1 (Figure 2C).
Figure 2. Effects of donepezil (A); tacrine (B); rivastigmine (C) and galantamine (D) on planarian seizure-like activity (pSLA) in Dugesia tigrina, after 5 min of exposure. Samples were tested in triplicate with 30 planarians in each Petri dish after 24 h of exposure. * Means differ by Dunnett’s test (p = 0.05).
Figure 2. Effects of donepezil (A); tacrine (B); rivastigmine (C) and galantamine (D) on planarian seizure-like activity (pSLA) in Dugesia tigrina, after 5 min of exposure. Samples were tested in triplicate with 30 planarians in each Petri dish after 24 h of exposure. * Means differ by Dunnett’s test (p = 0.05).
Molecules 21 00053 g002
We also observed effects provoked by the drugs, such as convulsions and locomotor retardment, confirming the results described for other pharmacological models [26,28,29,30,31]. Myhrer et al. [26] reported that rats treated via intraperitoneal injection with galantamine exhibited a cognitive deficit in terms of reduced preference, also observed for donepezil; the locomotor activity was radically depressed in all groups treated with anticholinesterasics, as well as in combination with procyclidine, but was more prominent in rats injected only with galantamine.
Regarding the number of crossed lines (planarian locomotor velocity (pLMV)), we observed that the drugs reduced the locomotor capacity in D. tigrina. Donepezil and rivastigmine presented a lower effect compared to tacrine and galantamine during the observation period of 5 min (Figure 3A,D). Galantamine caused higher retardment of movements in D. tigrina, with 10 crossed lines during the 5-min observation (Figure 3C). D. tigrina exhibited the characteristic of constant pLMV over the observation period, with 18 grid lines per minute in the control with artificial lake water. The concentration of 5 μg·mL−1 did not cause a significant reduction by the tested drugs, with a mean of 8–17 lines crossed per minute (Figure 3A–D). A low convulsant activity under the highest doses was similar to the loss of motility at the same concentrations. Galantamine most affected D. tigrina in pSLA and pLMV (Figure 2 and Figure 3C). The results of the locomotion delay can be explained by a non-uniform distribution of the drugs used, as demonstrated for tacrine, talantamine and physostigmine; these accumulate in the brain tissue of small animals [32], and this accumulation (or bioavailability) could be a reason for the different concentrations for inhibition in vivo.
Figure 3. Effects of donepezil (A) tacrine (B); rivastigmine (C) and galantamine (D) on motility (planarian locomotor velocity (pLMV)) in Dugesia tigrina, after 5 min of exposure. Samples were tested in triplicate with 30 planarians in each Petri dish.
Figure 3. Effects of donepezil (A) tacrine (B); rivastigmine (C) and galantamine (D) on motility (planarian locomotor velocity (pLMV)) in Dugesia tigrina, after 5 min of exposure. Samples were tested in triplicate with 30 planarians in each Petri dish.
Molecules 21 00053 g003
The inhibitors of AChE can provoke convulsions induced by nervous agents and may have lethal effects. Myhrer et al. [26] reported that physostigmine (0.1 mg·kg−1), galantamine (3 mg·kg−1), huperzine (0.5 mg·kg−1) and donepezil (2.5 mg·kg−1) provoke locomotion retardment in all treated groups, with more prominent effects for galantamine, as we also observed in our study.
It is probable that the increase in cholinergic activity in the brain is related to an initial phase of convulsions [33,34], while the established convulsions are probably associated with increased glutamatergic activity, leading to neural damage predominantly in the hippocampus, pyriform cortex and entorhinal cortex [34,35].
In future studies, it will be important to clarify the possible role of the activity of subclinical apprehension in the neuropathological syndrome induced by the treatment with the tested drugs. We considered it probable that the animals, including those that remain relatively motionless with behavioral signs of minimal convulsive activity, treated with different concentrations of drugs, in particular galantamine, underwent discharges of the convulsive crisis, which increase the synaptic concentrations. Other studies demonstrated that donepezil causes hypothermia, hypoactivity and diarrhea after administration of 1.25 mg·kg−1. Such symptoms may be associated with lethality, being implications associated with disturbances of the nervous system [36]. The administration of tacrine to treat Alzheimer’s disease causes hepatotoxicity in 30%–50% of patients, indicated by increased levels of transaminases [37].
Our results add to other studies that demonstrate the use of D. tigrina in pharmacological models, such as trials on regeneration and alterations in glycolytic metabolism [38], chemo-convulsants [15], interactions of acetylcholine and dopamine [39], the increase of mobility and the proliferation of stem cells [40], morphogenesis [14], bipolar regeneration [14,17], convulsive activity [15], locomotion retardment [41] physical dependence [42] and the production of serotonin [43].
These results suggest that pLMV can serve as a practical and valuable model to complement studies on the inhibition of AChE in planarians, which could be utilized as an in vivo model. The models of rats most utilized only include the inhibition of AChE in rat brains, indicated by various already known drugs [33,34,35,39], beside the reduction in locomotor ability [44,45]. The planarian model has the advantages of an invertebrate over a vertebrate model. Raffa et al. [44] have demonstrated that the planarian model gives a quantifiable approach, sensitive for studies on dopamine receptors, and stated that this method can be applied to study pharmacological and toxic agents and drugs of abuse. Planarians are sensitive due to a diffuse nervous system. Therefore, the behavioral sensitization in mammals, including human beings, is affected by the administration type and experimental environment, and some results may not have any relation to drugs that are difficult to eliminate. More simple animals and those less susceptible to such confounding influences can be advantageous substitutes for studies concerning the nervous system. Rawls et al. [45] reported that the inability to control those factors associated with sensitivities can hinder the interpretation of results in mammals.
Changes in behavior have been little studied in invertebrates, and planarians became attractive organisms to investigate the process of behavioral sensitization. Even more importantly, planarians exhibit hyperactivity or hypoactivity after acute exposure to drugs, allowing quantifying alterations in behavior.
Planarians have key substrates that were identified as primary mediators of behavioral sensitization [45], they being: (1) establish to studying behavioral sensitization as a simple biological parameter that is sensitive, reproducible, quantifiable, cost-effective and time-effective; (2) to minimize interpretive complications related to pharmacokinetic factors, such as drug absorption, distribution, metabolism and elimination; (3) to precisely identify the drug concentration, as opposed to just the dose, which is less amenable to rigorous quantitative analysis; (4) to continuously expose the animal to a drug (soaking it in a Petri dish), a feat accomplished easily with planarians because of their aquatic nature, thus offering a distinct advantage over mammalian models that rely on multiple injections or mini-pumps to achieve constant drug concentrations; (5) to reduce the impact of higher-order confounding influences, such as handling, familiarity of the testing environment, strain, stress from procedures and anticipation of drug administration; (6) to adapt the model of behavioral sensitization to translational use, such as preclinical testing and in vivo screening of very small amounts, allowing one to investigate its potential in CNS; (7) to study the effects of poly-drug exposure, particularly as related to screening compounds for their efficacy against the adverse effects produced by simultaneous exposure; and (8) to reduce the use of mammals in research.
Hence, our study reinforces the potential use of D. tigrina as experimental models of inhibition of acetylcholinesterase in the search for new substances that could be utilized in the treatment of Alzheimer’s disease. Models that utilize D. tigrina are even more attractive for the easiness of maintaining and manipulating them under laboratory conditions and are of low cost in comparison to other models of test animals.

3. Experimental Section

3.1. Collection and Acclimation of D. tigrina

Samples of D. tigrina were collected from the lake of the Barigui Park, city of Curitiba, PR, Brazil, at the coordinates 25°25′34.52′′ S, 49°18′27.03′′ W. The planarians were taken to the laboratory, and individuals ca. 6–10 mm were separated, enclosed in plastic trays with artificial lake water (6 mM NaCl, 0.1 mM NaHCO3, 0.6 mM CaCl2) and the pH adjusted to 6.9 with a solution of NaOH 1 N [31]. Next, the tray was taken to a BOD-Biological Organisms Development (Model MA-403, Marconi) chamber, under adequate conditions of temperature (20 °C) and relative humidity (80%) [46], for 24 h before the bioassays.

3.2. Evaluation of Mortality

The drugs galantamine, donepezil, rivastigmine and tacrine were chosen for being utilized in treatment of Alzheimer’s disease. All drugs were obtained from Sigma Aldrich®, and the concentrations of 5, 10, 15, 20 and 25 μg·mL−1 were prepared for utilization in the trials, being previously dissolved in DMSO 0.1%, followed by distilled water.
The choice of concentrations was based on a pre-mortality test with concentrations ranging from 5–100 μg·mL−1. From the pre-test, we decided to use concentrations of 5–25 μg·mL−1. Such concentrations were chosen because >25 μg·mL−1 caused 100% mortality. Drugs were diluted in DMSO, because they are not soluble in other solvents. DMSO concentrations higher than 0.1% caused changes in the behavior of planarians and were therefore discarded.
The pH of the solutions was adjusted to 6.9 with KOH 1 N using a pH meter (MPA 210, Tecnopar, Curitiba, PR) and put in plastic pots of 5 mL. Trials were performed in three Petri dishes containing 30 planarians on each plate. In the control, the same conditions of the tests conducted for the drugs were used, only DMSO solution 0.1% being added to the water.
After the acclimation period, 15 individuals were placed in each Petri dish (9 cm diameter) and included in the test solutions with the different concentrations, totaling 1080 (thousands eighty) individuals utilized for the trial, and exposed during 24 h (standard exposure time for acute toxicity), where 3 replicates were used for each concentration. All time points chosen for these tests are based on other reported studies for other aquatic organisms [47,48,49,50,51,52]. After this period of exposure, the number of dead individuals was recorded. In this trial, we considered dead the individuals that did not respond to stimuli of light or when touched. The collected data were submitted to probit analysis, to calculate the results regarding LC50, which was determined by nonlinear regression using the Probitos program [53].

3.3. Preparation of the Enzymatic Extract

To evaluate the enzymatic activity, the planarians were submitted to the test solutions during a period of 6 h; then, drugs were removed, and the planarians were gently washed with artificial lake water, at least three times. Next, the planarians were placed in a porcelain mortar and homogenized in 900 μL of 0.1 M buffer phosphate (pH 7.5) containing 0.1% (v/v) of Triton X-100 and 100 μL of protease inhibitors (Sigma Aldrich®, St. Louis, MO, USA) and centrifuged at 12,000 rpm, 20 min at 4 °C [54]. Supernatants were gathered and utilized as source of enzymes for the determination of AChE and total proteins. The concentration of total proteins of each enzymatic extract was determined, using bovine serum albumin (Sigma Aldrich®) as a standard [55].

3.4. Determination of Acetylcholinesterase

The activities of acetylcholinesterase (AChE) were performed according to the modified procedure of Ellman [56]. The activity of AChE was determined after the reaction of the Ellman reagent (DTNB-5,5′-Dithiobis-(2-Nitrobenzoic Acid)) and the thiocholine generated by enzymatic hydrolysis of acetylthiocholine iodide (ATCH), respectively, by the addition of 100 μL of enzymatic extract (1.3–1.8 mg of protein of enzyme extract), 800 μL of buffer PBS 1 × (pH 7.4), 100 μL of DTNB (3,3′-Dithio-bis (6-nitrobenzoic acid) and 200 μL of ATCH 1 mM. The reagents were obtained from Sigma Aldrich®. Next, 300 μL of the samples were transferred to 96-well microplates and the absorbance read at 412 nm (thermo scientific multiscan FC model microplate reader). The results were expressed in μmol·min−1, to which all described enzymes the enzymatic extracts were added, with the specific reagent solutions for each enzymatic dosage.

3.5. Measures of Seizure-Like Activity

The convulsant activity by means of measurements of seizure-like activities (planarian seizure-like activity (pSLA)) is defined as asynchronous paroxysms resulting in a sudden interruption of the spontaneous normal locomotor activity, and observed convulsive movements, such as posture similar to C-like, screw-like, snake-like and walnut position, hyperkinesia and hypokinesia, which are very different from normal locomotor movements [41].
The duration of each behavior is approximately 1 s. To measure pSLA, the individuals were placed in glass Petri dishes (60 × 15 mm) containing the solutions at different concentrations of the drugs and artificial lake water. The exposure time was 5 min. The accumulation of pSLA 5 min was calculated as the number of observed behavior per minute, during the 5-min exposure, according to the parameters established by Raffa et al. [44]. Each planarian was tested only once to determine the convulsive effect [15], and the counting of pSLA was done double-blind.

3.6. Motility Measurement (pLMV)

The locomotion delay in D. tigrina was evaluated by means of trials of pLMV (planarian locomotor velocity). In this procedure, 15 individuals were individually placed in Petri dishes (9 cm diam) containing 5.0 mL of solution of the drugs in the same concentrations utilized in the previous trials. The pLMV and pSLA provided a stable baseline behavior against which to compare the action of pharmacologic test agents and, after 5 min of exposure, did not show changes in behavior [44].
The exposure time to the drug followed the protocol of Raffa et al. [44]. After 5 min of exposure, the planarians were washed 3 times with distilled water and placed in Petri dishes with 5.0 mL of chlorine-free water. The Petri dishes were placed on millimeter-ruled paper with a 0.5-mm distance, and the pLMV was quantified by the observation of the accumulated number of lines crossed by each planarian per minute. Each planarian was used only once [44].

3.7. Statistical Analysis

In the mortality assay, the experimental design was a completely randomized factorial 4 × 5, with an additional treatment (control), totaling 21 treatments (4 × 5 + 1), with three replicates for each treatment. All values were expressed as the mean ± SEM, and for the comparison of the results regarding the number of dead individuals, the AChE levels were assessed utilizing analysis of variance (ANOVA) followed by a post hoc Dunnett’s test for the analysis of the detailed data. The level of significance was p = 0.05. The locomotor velocity (pSLA and pLMV) is expressed as the mean (±SEM) of the cumulative number of grid lines crossed by each planarian per minute. Relative potency was calculated from linear regression analysis of individual dose-response curves, according to the protocol established by Raffa et al. [44].

4. Conclusions

These results demonstrate that D. tigrina can be used as a model for the investigation of AChE inhibitory substances, because they are low maintenance with respect to manipulating them under laboratory conditions and are low cost in comparison to other models of test animals.

Acknowledgments

The authors are grateful to Cassiano Cesar Host Caluff for taxonomical identifications; CAPES (Comissão de aperfeiçoamento de pessoal de nível superior) for the award of the research scholarship during the tenure of this work.

Author Contributions

C.B.S., A.P., S.E.E., L.M.B, M.O. and K.F.N. designed and performed research; J.F.G.D., M.O., L.M.B and S.M.W.Z. performed research and Analyzed data; O.G.M., A.P., L.D. and M.D.M. analyzed data; C.B.S. and A.P. wrote the paper; K.F.N. Contributed new reagents/analytic tools.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Roberson, M.R.; Harrell, L.E. Cholinergic activity and amyloid precursor protein metabolism. Brain Res. Rev. 1997, 25, 50–69. [Google Scholar] [CrossRef]
  2. McGeer, E.G.; McGeer, P.L. Clinically tested drugs for Alzheimer’s disease. Expert Opin. Investig. Drugs 2003, 12, 1143–1151. [Google Scholar] [CrossRef] [PubMed]
  3. Oboh, G.; Ademiluyi, A.O.; Akinyemi, A.J. Inhibition of acetylcholinesterase activities and some pro-oxidant induced lipid peroxidation in rat brain by two varieties of ginger (Zingiber officinale). Exp. Toxicol. Pathol. 2012, 64, 315–319. [Google Scholar] [CrossRef] [PubMed]
  4. Mejri, N.; Said, N.M.; Guizani, S.; Essouissi, I.; Saidi, M. Preliminary studies of acetylcholinesterase activity in the rat brain using N-phenylferrocenecarboxamide labelled by the technetium-99. Nucl. Med. Biol. 2013, 40, 561–566. [Google Scholar] [CrossRef] [PubMed]
  5. Ozarowski, M.; Mikolajczak, P.L.; Bogacz, A.; Gryszczynska, A.; Kujawska, M.; Jodynis-Liebert, J.; Piasecka, A.; Napieczynska, H.; Szulc, M.; Kujawski, R.; et al. Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia 2013, 91, 261–271. [Google Scholar] [CrossRef] [PubMed]
  6. Singh, M.; Kaur, M.; Kukreja, H.; Chugh, R.; Silakari, O.; Singh, D. Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection. Eur. J. Med. Chem. 2013, 70, 165–188. [Google Scholar] [CrossRef] [PubMed]
  7. Yang, W.N.; Han, H.; Hu, X.D.; Feng, G.F.; Qian, Y.H. The effects of perindopril on cognitive impairment induced by d-galactose and aluminum trichloride via inhibition of acetylcholinesterase activity and oxidative stress. Pharmacol. Biochem. Behav. 2013, 114–115, 31–36. [Google Scholar] [CrossRef] [PubMed]
  8. Pagán, O.R.; Deats, S.; Baker, D.; Montgomery, E.; Wilk, G.; Tenaglia, M.; Semon, J. Planarians require an intact brain to behaviorally react to cocaine, but not to react to nicotine. Neuroscience 2013, 246, 265–270. [Google Scholar] [CrossRef] [PubMed]
  9. Cebria, F. Regenerating the central nervous system: How easy for planarians! Dev. Genes Evol. 2007, 217, 733–748. [Google Scholar] [CrossRef] [PubMed]
  10. Cebria, F.; Nakazawa, M.; Mineta, K.; Ikeo, K.; Gojobori, T.; Agata, K. Dissecting planarian central nervous system regeneration by the expression of neural-specific genes. Dev. Growth Differ. 2002, 44, 135–146. [Google Scholar] [CrossRef] [PubMed]
  11. Aoki, R.; Wake, H.; Sasaki, H.; Agata, K. Recording and spectrum analysis of the planarian electroencephalogram. Neuroscience 2009, 159, 908–914. [Google Scholar] [CrossRef] [PubMed]
  12. Farrell, M.S.; Gilmore, K.; Raffa, R.B.; Walker, E.A. Behavioral characterization of serotonergic activation in the flatworm Planaria. Behav. Pharmacol. 2008, 19, 177–182. [Google Scholar] [CrossRef] [PubMed]
  13. Nishimura, K.; Kitamura, Y.; Umesono, Y.; Takeuchi, K.; Takata, K.; Taniguchi, T.; Agata, K. Identification of glutamic acid decarboxylase gene and distribution of GABAergic nervous system in the planarian Dugesia japonica. Neuroscience 2008, 153, 1103–1114. [Google Scholar] [CrossRef] [PubMed]
  14. Gentile, L.; Cebria, F.; Bartscherer, K. The planarian flatworm: An in vivo model for stem cell biology and nervous system regeneration. Dis. Model. Mech. 2011, 4, 12–19. [Google Scholar] [CrossRef] [PubMed]
  15. Ramakrishnan, L.; Desaer, C. Carbamazepine inhibits distinct chemoconvulsant-induced seizure-like activity in Dugesia tigrina. Pharmacol. Biochem. Behav. 2011, 99, 665–670. [Google Scholar] [CrossRef] [PubMed]
  16. Forsthoefel, D.J.; James, N.P.; Escobar, D.J.; Stary, J.M.; Vieira, A.P.; Waters, F.A.; Newmark, P.A. An RNAi screen reveals intestinal regulators of branching morphogenesis, differentiation, and stem cell proliferation in planarians. Dev. Cell 2012, 23, 691–704. [Google Scholar] [CrossRef] [PubMed]
  17. Isolani, M.E.; Pietra, D.; Balestrini, L.; Borghini, A.; Deri, P.; Imbriani, M.; Bianucci, A.M.; Batistoni, R. The in vivo effect of chelidonine on the stem cell system of planarians. Eur. J. Pharmacol. 2012, 686, 1–7. [Google Scholar] [CrossRef] [PubMed]
  18. Caricati-Neto, A.; D’Angelo L, C.; Reuter, H.; Hyppolito Jurkiewicz, N.; Garcia, A.G.; Jurkiewicz, A. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens. Eur. J. Pharmacol. 2004, 503, 191–201. [Google Scholar] [CrossRef] [PubMed]
  19. Geerts, H.; Guillaumat, P.O.; Grantham, C.; Bode, W.; Anciaux, K.; Sachak, S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res. 2005, 1033, 186–193. [Google Scholar] [CrossRef] [PubMed]
  20. Porcel, J.; Montalban, X. Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis. J. Neurol. Sci. 2006, 245, 177–181. [Google Scholar] [CrossRef] [PubMed]
  21. Yanagida, T.; Takeuchi, H.; Kitamura, Y.; Takata, K.; Minamino, H.; Shibaike, T.; Tsushima, J.; Kishimoto, K.; Yasui, H.; Taniguchi, T.; et al. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci. Res. 2008, 62, 254–261. [Google Scholar] [CrossRef] [PubMed]
  22. Jonckers, E.; van der Linden, A.; Verhoye, M. Functional magnetic resonance imaging in rodents: An unique tool to study in vivo pharmacologic neuromodulation. Curr. Opin. Pharmacol. 2013, 13, 813–820. [Google Scholar] [CrossRef] [PubMed]
  23. Orhan, I.E.; Senol, F.S.; Ercetin, T.; Kahraman, A.; Celep, F.; Akaydin, G.; Sener, B.; Dogan, M. Assessment of anticholinesterase and antioxidant properties of selected sage (Salvia) species with their total phenol and flavonoid contents. Ind. Crop. Prod. 2013, 41, 21–30. [Google Scholar] [CrossRef]
  24. Ribeiro, P.; El-Shehabi, F.; Patocka, N. Classical transmitters and their receptors in flatworms. Parasitology 2005, 131, S19–S40. [Google Scholar] [CrossRef] [PubMed]
  25. Bajgarl, J.; Fusek, J.; Skopec, F. Changes of cholinesterases in the blood and some tissues following administration of tacrin and its two derivatives to rats. Neurochem. Int. 1994, 24, 555–558. [Google Scholar] [CrossRef]
  26. Myhrer, T.; Enger, S.; Aas, P. Antiparkinson drugs used as prophylactics for nerve agents: Studies of cognitive side effects in rats. Pharmacol. Biochem. Behav. 2008, 89, 633–638. [Google Scholar] [CrossRef] [PubMed]
  27. Scali, C.; Casamenti, F.; Bellucci, A.; Costagli, C.; Schmidt, B.; Pepeu, G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J. Neural Transm. 2002, 109, 1067–1080. [Google Scholar]
  28. Braga, M.F.; Harvey, A.L.; Rowan, E.G. Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro. Br. J. Pharmacol. 1991, 102, 909–915. [Google Scholar] [CrossRef] [PubMed]
  29. Creeley, C.E.; Wozniak, D.F.; Nardi, A.; Farber, N.B.; Olney, J.W. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol. Aging 2008, 29, 153–167. [Google Scholar] [CrossRef] [PubMed]
  30. Lai, D.-H.; Yang, Z.-D.; Xue, W.-W.; Sheng, J.; Shi, Y.; Yao, X.-J. Isolation, characterization and acetylcholinesterase inhibitory activity of alkaloids from roots of Stemona sessilifolia. Fitoterapia 2013, 89, 257–264. [Google Scholar] [CrossRef] [PubMed]
  31. Santos-Bueso, E.; Serrador-Garcia, M.; Garcia-Sanchez, J. [Donepezil as treatment of Charles Bonnet syndrome]. Arch. Soc. Esp. Oftalmol. 2013, 88, 369–370. [Google Scholar] [CrossRef] [PubMed]
  32. Thomsen, T.; Kaden, B.; Fischer, J.P.; Bickel, U.; Barz, H.; Gusztony, G.; Cervos-Navarro, J.; Kewitz, H. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigrnine and tacrine. Eur. J. Clin. Chem. Clin. Biochem. 1991, 29, 487–492. [Google Scholar] [PubMed]
  33. Lallement, G.; Denoyer, M.; Collet, A.; Pernot-Marino, I.; Baubichon, D.; Monmaur, P.; Blanchet, G. Changes in hippocampal acetylcholine and glutamate extracellular levels during soman-induced seizures: Influence of septal cholinoceptive cells. Neurosci. Lett. 1992, 139, 104–107. [Google Scholar] [CrossRef]
  34. McDonough, J.H., Jr.; Shih, T.M. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci. Biobehav. Rev. 1997, 21, 559–579. [Google Scholar] [CrossRef]
  35. Carpentier, P.; Lambrinidis, M.; Blanchet, G. Early dendritic changes in hippocampal pyramidal neurones (field CA1) of rats subjected to acute soman intoxication: A light microscopic study. Brain Res. 1991, 541, 293–299. [Google Scholar] [CrossRef]
  36. Janowsky, D.S.; Davis, J.M.; Overstreet, D.H. Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: A potential nerve agent treatment. Pharmacol. Biochem. Behav. 2005, 81, 917–922. [Google Scholar] [CrossRef] [PubMed]
  37. Lagadic-Gossmann, D.; Rissel, M.; Le Bot, M.A.; Guillouzo, A. Toxic effects of tacrine on primary hepatocytes and liver epithelial cells in culture. Cell Biol. Toxicol. 1998, 14, 361–373. [Google Scholar] [CrossRef] [PubMed]
  38. Torres-Da Matta, J.; Kanaan, S.; Nery da Mata, A. Changes in glycolytic metabolism during the regeneration of planarians Dugesia tigrina (Girard). Comp. Biochem. Physiol. B Comp. Biochem. 1989, 93, 391–396. [Google Scholar] [CrossRef]
  39. Buttarelli, F.R.; Pontieri, F.E.; Margotta, V.; Palladini, G. Acetylcholine/dopamine interaction in planaria. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2000, 125, 225–231. [Google Scholar] [CrossRef]
  40. Wu, H.P.; Persinger, M.A. Increased mobility and stem-cell proliferation rate in Dugesia tigrina induced by 880nm light emitting diode. J. Photochem. Photobiol. 2011, 102, 156–160. [Google Scholar] [CrossRef] [PubMed]
  41. Rawls, S.M.; Thomas, T.; Adeola, M.; Patil, T.; Raymondi, N.; Poles, A.; Loo, M.; Raffa, R.B. Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol. Biochem. Behav. 2009, 93, 363–367. [Google Scholar] [CrossRef] [PubMed]
  42. Raffa, R.B.; Cavallo, F.; Capasso, A. Flumazenil-sensitive dose-related physical dependence in planarians produced by two benzodiazepine and one non-benzodiazepine benzodiazepine-receptor agonists. Eur. J. Pharmacol. 2007, 564, 88–93. [Google Scholar] [CrossRef] [PubMed]
  43. Fernandes, M.C.; Alvares, E.P.; Gama, P.; Silveira, M. Serotonin in the nervous system of the head region of the land planarian Bipalium kewense. Tissue Cell 2003, 35, 479–486. [Google Scholar] [CrossRef]
  44. Raffa, R.B.; Holland, L.J.; Schulingkamp, R.J. Quantitative assessment of dopamine D2 antagonist activity using invertebrate (Planaria) locomotion as a functional endpoint. J. Pharmacol. Toxicol. Methods 2001, 45, 223–226. [Google Scholar] [CrossRef]
  45. Rawls, S.M.; Patil, T.; Yuvasheva, E.; Raffa, R.B. First evidence that drugs of abuse produce behavioral sensitization and cross-sensitization in planarians. Behav. Pharmacol. 2010, 21, 301–313. [Google Scholar] [CrossRef] [PubMed]
  46. Guecheva, T.N.; Erdtmann, B.; Benfato, M.S.; Henriques, J.A.P. Stress protein response and catalase activity in freshwater planarian Dugesia (Girardia) schubarti exposed to copper. Ecotoxicol. Environ. Saf. 2003, 56, 351–357. [Google Scholar] [CrossRef]
  47. Rowlands, A.L.; Pagán, O.R. Parthenolide prevents the expression of cocaine-induced withdrawal behavior in planarians. Eur. J. Pharmacol. 2008, 583, 170–172. [Google Scholar] [CrossRef] [PubMed]
  48. Pagán, O.R.; Rowlands, A.L.; Azam, M.; Urban, K.R.; Bidja, A.H.; Roy, D.M.; Feeney, R.B.; Afshari, L.K. Reversal of cocaine-induced planarian behavior by parthenolide and related sesquiterpene lactones. Pharmacol. Biochem. Behav. 2008, 89, 160–170. [Google Scholar]
  49. Geethaa, S.; Thavamany, P.J.; Chiew, S.P.; Thong, O.M. Interference from ordinarily used solvents in the outcomes of Artemia salina lethality test. J. Adv. Pharm. Technol. Res. 2013, 4, 179–182. [Google Scholar] [PubMed]
  50. Stevens, A.S.; Pirotte, N.; Plusquin, M.; Willems, M.; Neyens, T.; Artois, T.; Smeets, S. Toxicity profiles and solvent–toxicant interference in the planarian Schmidtea mediterranea after dimethylsulfoxide (DMSO) exposure. J. Appl. Toxicol. 2015, 35, 319–326. [Google Scholar] [CrossRef] [PubMed]
  51. Chen, T.H.; Wang, Y.H.; Wu, Y.H. Developmental exposures to ethanol or dimethylsulfoxide at low concentrations alter locomotor activity in larval zebrafish: Implications for behavioral toxicity bioassays. Aquat. Toxicol. 2011, 102, 162–166. [Google Scholar] [CrossRef] [PubMed]
  52. Barbosa, I.R.; Martins, R.M.; Sá, E.; Melo, M.L.; Soares, A.M. Acute and chronic toxicity of dimethylsulfoxide to Daphnia magna. Bull. Environ. Contam. Toxicol. 2003, 70, 1264–1268. [Google Scholar] [CrossRef] [PubMed]
  53. Finney, D.J. Probit Analysis, 3rd ed.; Cambridge University Press: Cambridge, UK, 1971. [Google Scholar]
  54. Zhang, X.; Zhang, B.; Yi, H.; Zhao, B. Mortality and antioxidant responses in the planarian (Dugesia japonica) after exposure to copper. Toxicol. Ind. Health 2014, 30, 123–131. [Google Scholar] [CrossRef] [PubMed]
  55. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265–275. [Google Scholar] [PubMed]
  56. Isomae, K.; Morimoto, S.; Hasegawa, H.; Morita, K.; Kamei, J. Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur. J. Pharmacol. 2003, 465, 97–103. [Google Scholar] [CrossRef]
  • Sample Availability: Samples of the compounds isolated comercial donepezil, tacrin, galantamin and rivastigmin are available from the authors.

Share and Cite

MDPI and ACS Style

Bezerra da Silva, C.; Pott, A.; Elifio-Esposito, S.; Dalarmi, L.; Fialho do Nascimento, K.; Moura Burci, L.; De Oliveira, M.; De Fátima Gaspari Dias, J.; Maria Warumby Zanin, S.; Gomes Miguel, O.; et al. Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina. Molecules 2016, 21, 53. https://doi.org/10.3390/molecules21010053

AMA Style

Bezerra da Silva C, Pott A, Elifio-Esposito S, Dalarmi L, Fialho do Nascimento K, Moura Burci L, De Oliveira M, De Fátima Gaspari Dias J, Maria Warumby Zanin S, Gomes Miguel O, et al. Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina. Molecules. 2016; 21(1):53. https://doi.org/10.3390/molecules21010053

Chicago/Turabian Style

Bezerra da Silva, Cristiane, Arnildo Pott, Selene Elifio-Esposito, Luciane Dalarmi, Kátia Fialho do Nascimento, Ligia Moura Burci, Maislian De Oliveira, Josiane De Fátima Gaspari Dias, Sandra Maria Warumby Zanin, Obdulio Gomes Miguel, and et al. 2016. "Effect of Donepezil, Tacrine, Galantamine and Rivastigmine on Acetylcholinesterase Inhibition in Dugesia tigrina" Molecules 21, no. 1: 53. https://doi.org/10.3390/molecules21010053

Article Metrics

Back to TopTop